EASL 2024 – Die Highlights

Between 5th and 8th June 2024, almost 7,000 people from around the world gathered in Milan, Italy, for the 59th Congress of the European Association for the Study of the Liver (EASL).

Zielgruppe: Praxis-Ärzt*innen, Diabetolog*innen, Gastroenterolog*innen, Klinik-Ärzt*innen, Adipositas Ärzt*innen, Internist*innen

ESC2023 DIAB395

This event showcased key advancements in hepatology, unveiling potential game-changers in liver care such as innovative microbiota transplants, new drugs in development, and intelligent testing platforms.

The research presented at this year’s congress exemplifies our commitment to advancing liver disease treatment.
We are witnessing a new era of innovation that will bring tangible benefits to patients globally.

Aleksander Krag

EASL Secretary General

EASL 2024 in numbers
 

7,568

participants

(incl. 656 online)

117

countries

188

scientific

sessions

1,887

accepted

abstracts


8 key themes:
 

General hepatology; metabolism, alcohol and toxicity; cirrhosis and complications; liver tumors; viral hepatitis; immune-mediated and cholestatic diseases; public health; and basic science

Downloads

Referent

Prof. Dr. med. Jörn M. Schattenberg
Professor für Innere Medizin - Gastroenterologie, Hepatologie, Endokrinologie und Ernährungsmedizin, Universität des Saarlandes

Oral presentations
  • Results of the SYNERGY-NASH phase 2 trial on tirzepatide for the treatment of people with MASH and F2/F3 fibrosis
  • Efficacy and safety data from the HARMONY phase 2b study assessing efruxifermin vs placebo over 96 weeks in people with MASH and F2/F3 fibrosis
  • Outcomes from a 51-week phase 2 trial on a novel DGAT2 antisense inhibitor for the treatment of people with MASH and F2/F3 fibrosis
  • Data from the FASCINATE-2 phase 2b study, including efficacy and safety outcomes of the FASN inhibitor denifanstat vs placebo in people with MASH and F2/F3 fibrosis
  • Study reporting 15-year liver outcomes after metabolic surgery in people with compensated cirrhosis due to MASH

 

Poster presentations

  • Results from the phase 3 REGENERATE trial evaluating obeticholic acid in patients with pre-cirrhotic fibrosis due to MASLD

DGAT, diglyceride acyltransferase; EASD, European Association for the Study of Diabetes; EASL, European Association for the Study of the Liver; EASO, European Association for the Study of Obesity; F, fibrosis; MASLD, metabolic dysfunction-associated steatotic liver disease; MASH, metabolic dysfunction-associated steatohepatitis; NCD, noncommunicable disease; SLD, steatotic liver disease; T2D, type 2 diabetes; WHO, World Health Organization 


References

1. Cheemerla S and Balakrishnan M. Clin Liver Dis. 2021; 17:365–370

2. Devarbhavi H, et al. J Hepatol. 2023; 79:516–537

3. Macpherson I, et al. Frontline Gastroenterol. 2022; doi: 0.1136/flgastro-2021-101833

4. Younossi ZM, et al. Clin Gastroenterol Hepatol 2023;21:1978–1991

5. EASD, EASO, EASL. J Hepatol. 2024; doi: 10.1016/j.jhep.2024.04.031